Bank of Montreal Can Has $677,000 Stock Position in Sarepta Therapeutics, Inc. $SRPT

Bank of Montreal Can lowered its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 99.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,596 shares of the biotechnology company’s stock after selling 53,110,514 shares during the quarter. Bank of Montreal Can’s holdings in Sarepta Therapeutics were worth $677,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in SRPT. Ancora Advisors LLC grew its position in Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of Sarepta Therapeutics in the first quarter worth $44,000. Pandora Wealth Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at $45,000. Brooklyn Investment Group raised its position in Sarepta Therapeutics by 450.4% during the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 590 shares during the period. Finally, Blue Trust Inc. lifted its stake in Sarepta Therapeutics by 542.3% in the 2nd quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 2,771 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Up 5.6%

Sarepta Therapeutics stock opened at $18.81 on Monday. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $138.81. The firm’s fifty day simple moving average is $20.25 and its 200-day simple moving average is $23.91. The company has a market capitalization of $1.97 billion, a P/E ratio of -21.62 and a beta of 0.52.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. During the same period in the previous year, the company earned $0.62 earnings per share. The company’s quarterly revenue was down 14.5% compared to the same quarter last year. Sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Barclays lowered their target price on Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 5th. Wall Street Zen downgraded shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. BMO Capital Markets upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research report on Monday, September 22nd. Sanford C. Bernstein began coverage on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. They set a “market perform” rating and a $13.00 price target on the stock. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research note on Monday, August 25th. Eight analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $33.75.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.